Document is current
Any future updates will be listed below
-
Authors
Takamori, Hiroyuki https://orcid.org/0000-0002-0179-3335
Huang, Ying-Jung
Fukushima, Hidehito
Yokoyama, Kazuaki
Huang, Ting-Yu
Kuo, Ming-Chung
Ogawa, Seishi https://orcid.org/0000-0002-7778-5374
Nannya, Yasuhito https://orcid.org/0000-0002-6526-0992
Shih, Lee-Yung
- License Information
-
More Information
Article History
Received: 12 September 2024
Revised: 18 February 2025
Accepted: 19 March 2025
First Online: 31 March 2025
Competing interests
: SO reports a leadership position and advisory role with Eisai Co., Ltd and Chordia Therapeutics, Inc. SO is also a stockholder in Asahi Genomics Co., Ltd., and has received honoraria from The Mitsubishi Foundation and the Nakatani Foundation. Additionally, SO reports receiving grant/research funding from Chordia Therapeutics, Inc., Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd, and Nippon Shinyaku Co., Ltd. YN has received grant/research funding from Daiichi Sankyo Co., Ltd., ThinkCyte Co., Ltd., and Otsuka Pharmaceutical Co., Ltd. YN has also received honoraria from Bristol Myers Squibb Co., Ltd., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Novartis Pharma Co., Ltd., Pfizer Japan Co., Ltd., Nippon Shinyaku Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and AstraZeneca Co., Ltd. The remaining authors declare no competing financial interests related to this study.
